79 related articles for article (PubMed ID: 2379489)
21. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
22. Locoregional cellular immunotherapy for patients with advanced esophageal cancer.
Toh U; Yamana H; Sueyoshi S; Tanaka T; Niiya F; Katagiri K; Fujita H; Shirozou K; Itoh K
Clin Cancer Res; 2000 Dec; 6(12):4663-73. PubMed ID: 11156218
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
24. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
25. Immunologic assessment determined by response to IL-2 and immunophenotyping of tumor-infiltrating lymphocytes, of invaded and non invaded lymph nodes and of peripheral blood lymphocytes from twenty-one patients with primary laryngeal cancer.
Mantovani G; Maccio A; Zucca MV; Serra MC; Proto E; Locci F; Arangino V; Manduco D; Sulis G; Puxeddu P
J Biol Regul Homeost Agents; 1989; 3(1):25-34. PubMed ID: 2786668
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
27. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
28. Intra-lymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study.
Pizza G; Viza D; De Vinci C; Vich i Pascuchi JM; Busutti L; Bergami T
Lymphokine Res; 1988; 7(1):45-8. PubMed ID: 3283468
[TBL] [Abstract][Full Text] [Related]
29. Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer.
Kawaida H; Kono K; Takahashi A; Sugai H; Mimura K; Miyagawa N; Omata H; Ooi A; Fujii H
J Surg Res; 2005 Mar; 124(1):151-7. PubMed ID: 15734494
[TBL] [Abstract][Full Text] [Related]
30. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex.
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Noguchi K; Mizobata S; Tamai M; Hotta T; Arii K
Anticancer Res; 1994; 14(4A):1557-62. PubMed ID: 7979185
[TBL] [Abstract][Full Text] [Related]
31. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze MT; Grimm EA; Mazumder A; Strausser JL; Rosenberg SA
Cancer Res; 1981 Nov; 41(11 Pt 1):4420-5. PubMed ID: 6975652
[TBL] [Abstract][Full Text] [Related]
32. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
33. In vitro generation of immune effector cells from tumor-associated lymphocytes of human gastric cancer.
Kim HJ; Heo DS; Suh CI; Kim HT; Bang YJ; Kim NK
Anticancer Res; 1995; 15(4):1247-55. PubMed ID: 7654004
[TBL] [Abstract][Full Text] [Related]
34. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
35. [The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer].
Han D; Zhu X; Huang Z
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):454-6. PubMed ID: 10920882
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the effectiveness of regional interleukin-2 dependent adoptive immunocytotherapy of mice with transplanted rhabdomyosarcoma].
Semenova-Kobzar' RA; Iudin VM; Kushko LIa; Iakhimovich LV; Berezhnaia NM
Eksp Onkol; 1990; 12(3):50-2. PubMed ID: 2344825
[TBL] [Abstract][Full Text] [Related]
37. [Interferon-forming properties of the leukocytes in assessing the functional activity of the regional lymph nodes in cervical cancer].
Vorontsova AL; Vinnitskaia VK; Balitskiĭ KP; Ligirda FD
Vopr Onkol; 1979; 25(11):44-7. PubMed ID: 390875
[TBL] [Abstract][Full Text] [Related]
38. [Comparative evaluation of the lymphocyte reactivity at the level of the loco-regional and peripheral lymph nodes in presence of malignant neoplasms. Preliminary results].
Levi Della Vida A; Bertocci E; Silvestri D; Pagliari L; Stipa V
Ann Ital Chir; 1979; 51(5):491-8. PubMed ID: 555261
[No Abstract] [Full Text] [Related]
39. Effect of sizofiran on regional lymph nodes in patients with head and neck cancer.
Kano Y; Kakuta H; Hashimoto J
Biotherapy; 1996; 9(4):257-62. PubMed ID: 9012545
[TBL] [Abstract][Full Text] [Related]
40. [Interleukin 2 and local immunotherapy of head and neck cancer].
Wu H; Tu GY
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1991; 26(6):367-9. PubMed ID: 1811693
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
